The 36-month beta value for ATHA is also noteworthy at 2.84. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATHA is 35.30M, and at present, short sellers hold a 2.96% of that float. The average trading volume of ATHA on May 08, 2024 was 350.91K shares.
ATHA) stock’s latest price update
Athira Pharma Inc (NASDAQ: ATHA)’s stock price has soared by 10.66 in relation to previous closing price of 1.97. Nevertheless, the company has seen a gain of 10.66% in its stock price over the last five trading days. Zacks Investment Research reported 2024-02-28 that Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let’s find out.
ATHA’s Market Performance
ATHA’s stock has risen by 10.66% in the past week, with a monthly drop of -9.92% and a quarterly drop of -31.45%. The volatility ratio for the week is 6.52% while the volatility levels for the last 30 days are 6.95% for Athira Pharma Inc The simple moving average for the past 20 days is 2.81% for ATHA’s stock, with a -10.17% simple moving average for the past 200 days.
Analysts’ Opinion of ATHA
Many brokerage firms have already submitted their reports for ATHA stocks, with JMP Securities repeating the rating for ATHA by listing it as a “Mkt Outperform.” The predicted price for ATHA in the upcoming period, according to JMP Securities is $20 based on the research report published on October 17, 2022 of the previous year 2022.
Mizuho, on the other hand, stated in their research note that they expect to see ATHA reach a price target of $6. The rating they have provided for ATHA stocks is “Buy” according to the report published on July 07th, 2022.
Stifel gave a rating of “Hold” to ATHA, setting the target price at $5 in the report published on June 23rd of the previous year.
ATHA Trading at -17.78% from the 50-Day Moving Average
After a stumble in the market that brought ATHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.28% of loss for the given period.
Volatility was left at 6.95%, however, over the last 30 days, the volatility rate increased by 6.52%, as shares sank -13.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.25% lower at present.
During the last 5 trading sessions, ATHA rose by +10.66%, which changed the moving average for the period of 200-days by -31.01% in comparison to the 20-day moving average, which settled at $2.1000. In addition, Athira Pharma Inc saw -10.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATHA starting from Litton Mark James, who sale 4,820 shares at the price of $2.91 back on Jan 05 ’24. After this action, Litton Mark James now owns 144,397 shares of Athira Pharma Inc, valued at $14,026 using the latest closing price.
Worthington Mark, the General Counsel of Athira Pharma Inc, sale 2,412 shares at $2.91 during a trade that took place back on Jan 05 ’24, which means that Worthington Mark is holding 34,452 shares at $7,019 based on the most recent closing price.
Stock Fundamentals for ATHA
The total capital return value is set at -0.97. Equity return is now at value -64.42, with -56.25 for asset returns.
Based on Athira Pharma Inc (ATHA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -63.57. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 65.18.
Currently, EBITDA for the company is -126.12 million with net debt to EBITDA at 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.37.
Conclusion
In summary, Athira Pharma Inc (ATHA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
